Back to Search

EDWARD STADTMAUER, MD

MD

Hematology (Internal Medicine) Physician

NPI: 1457394744IndividualAccepts Medicare

Specialties, Licenses & Credentials

Internal Medicine Physician

Internal Medicine

Code: 207R00000X

MD034788E(PA)
Hematology & Oncology Physician

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

MD034788E(PA)
Medical Oncology Physician

Internal Medicine — Medical Oncology

Code: 207RX0202X

MD034788E(PA)
Hematology (Internal Medicine) PhysicianPrimary

Internal Medicine — Hematology

Code: 207RH0000X

MD034788E(PA)

CMS Specialties

PrimaryHEMATOLOGY

Additional

INTERNAL MEDICINEMEDICAL ONCOLOGY

Education

PERELMAN SCHOOL OF MED AT THE UNIVERSITY OF PENNSYLVANIA

Class of 1983

Research & Publications (20)

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
PMID 19302559·Eur J Haematol·2009
3-trial
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
PMID 18000495·Clin Adv Hematol Oncol·2007
8-other
Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
PMID 11970767·Clin Lymphoma·2002
6-review
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
PMID 12162910·Curr Oncol Rep·2002
6-review
Histamine dihydrochloride and interleukin-2 in the treatment of acute myeloid leukemia.
PMID 12068389·Semin Oncol·2002
6-review
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
PMID 10760307·N Engl J Med·2000
3-trial
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.
PMID 19509133·Clin Cancer Res·2009
3-trial
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).
PMID 19423744·Blood·2009
3-trial
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
PMID 19545290·Br J Haematol·2009
8-other
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
PMID 19554029·Leukemia·2009
6-review
Third consensus on medical treatment of metastatic breast cancer.
PMID 19608616·Ann Oncol·2009
6-review
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
PMID 19535777·J Natl Cancer Inst·2009
8-other
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
PMID 19363221·Blood·2009
3-trial
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
PMID 19170677·Br J Haematol·2009
3-trial
Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
PMID 19362979·Clin Lymphoma Myeloma·2009
6-review
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
PMID 19561323·Blood·2009
8-other
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
PMID 18850013·Bone Marrow Transplant·2009
8-other
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
PMID 19626046·Leukemia·2009
8-other
Chronic lymphocytic leukemia: new concepts and emerging therapies.
PMID 19169831·Curr Treat Options Oncol·2009
6-review
Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormality.
PMID 18819096·Am J Hematol·2008
5-case

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
3400 CIVIC CENTER BLVD
PHILADELPHIA, PA 19104

Location

Practice Location

3400 CIVIC CENTER BLVD, PHILADELPHIA, PA
(215) 615-5858

Quick Facts

NPI
1457394744
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
4
Locations
1
Years in Practice
43
Publications
20

Are you this provider?

Claim Your Profile